The fastest and safest method for detecting neutralising antibodies NAB's
The cPass™ technology allows for the rapid detection of total neutralizing antibodies (NAbs) in a sample by mimicking the interaction between the virus and the host cell. In order for a virus to infect a host cell, a viral receptor binding protein (RBD) first needs to interact with the host cell's membrane receptor protein (ACE2).
The virus-host interaction and subsequent viral infection of the host cell leads to the activation of an individual's immune response which generates a population of antibodies against the virus. Some of these antibodies can bind to the virus, but not necessarily block viral infection. Other antibodies can bind to the RBD in a way that blocks the interaction with the ACE2 receptor. The cPass™ technology helps to distinguish whether a sample contains NAbs that may specifically block the interaction and therefore the viral entry into the host cell.
The gold standard (virus neutralization assay) test for measuring Nabs requires the use of live virus, cells, highly skilled operators, and complex safety laboratory procedures (biosafety level 3) that are generally less sensitive and require several days to obtain results. In contrast, the cPass™ Neutralization Antibody Detection Kit can be rapidly conducted within an hour in most labs, and is also amenable to high throughput and fully automated testing.
Another key advantage of the cPass™ technology is that it is a highly specific and sensitive and in the same time isotype- and species-independent. Current antibody tests on the market are typically isotype-specific for just IgM or IgG, species specific for human antibodies only and cannot distinguish NAbs from other binding antibodies which do not possess neutralizing function.
Quick and safe way to boost herd immunity
This new technology enables more laboratories, which until now did not have access to such complex analyses, to accelerate the race towards immunity from COVID 19
No virus and invitro cells
cPass™ does not require the use of viruses or cells, making the work safer for the researcher or laboratory technician.
Can be used in most laboratories
The absence of viruses does not require highly skilled operators and complex security laboratory procedures (biosafety level 3), thus significantly reducing costs and time to obtain results.
Significant reduction in time and costs
The advantage of using specific proteins instead of viruses or pseudo-viruses makes analysis operations much simpler and faster, saving a huge ammount of resources.
Accurate and fast
Another key advantage of the cPass™ technology is that it is a highly specific and sensitive and in the same time isotype- and species-independent.
Current antibody tests on the market are typically isotype-specific for just IgM or IgG, species specific for human antibodies only and cannot distinguish NAbs from other binding antibodies which do not possess neutralizing function.
It can be easily adapted for high-throughput automated tests with serum or plasma, significantly increasing the fields of application.
© COPYRIGHT 2020 TWIN HELIX C.F. /P.IVA and n° Registro Imprese di Milano 05819650960 – REA Milano 1851394 Cap.Soc.Euro 50.000 i.v. - Società uninominale